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Summary 
A successful antitumor T  cell immune response involves induction, recruitment, and effector 
function of T cells. While B7/BB1 is known as a major costimulatory molecule in the induction 
of T  cell responses,  its role in T  cell recruitment and effector function is still unclear.  In this 
study, we show that introducing a major costimulatory molecule B7/BB1 into a major histo- 
compatibility complex class II-negative tumor cell line, J558, results in a drastic reduction of 
its tumorigenicity. The tumor rejection depends on CD8 T cells but not CD4 T cells. However, 
unlike the previous reports on melanoma cell lines, B7/BBl-transfected J558 cells fail to induce 
cross-protection against parental J558 cells. The B7/BBl-transfccted 0558-B7), but not untransfected 
J558 cells (J558-Neo)  induce a CD8 T  cell-dominant inflammatory response,  and the T  cells 
isolated from the tumor infiltrating lymphocytes (TIL) are polyclonal in terms of their T  cell 
receptor VB usage. Most surprisingly, the freshly prepared TIL have a potent, CD8 T cell-mediated 
cytotoxicity on tumor cells without any in vitro stimulation. The cytotoxic T lymphocyte (CTL) 
activity can be blocked by anti-CD8 monoclonal antibody (mAb). Interestingly, the CTL lyse 
J558-B7 about 10- to 80-fold more ef~dently than untransfectedJ558-Neo cells. This preferential 
lysis cannot be attributed to recognition of B7/BBl-derived antigen by the T cells. This finding, 
together with the lack of the cross-protection between the J558-B7 and J558-Neo, suggests that 
B7/BB1 can also function at the effector phase of CTL responses. This notion is confirmed by 
our findings that the lysis of J558-B7 can be blocked by anti-B7 mAbs. Taken together, our 
results indicate that not only can the B7/BB1 molecule function as a costimulatory molecule 
at the initiation of immune response,  it can also play a major role in T  cell recruitment and 
effector function. This conclusion has significant  implications for immunotherapy of tumors. 
T  cells are the main effector cells in antitumor immune 
responses (1). Activation of tumor-specific T cells is there- 
fore crucial for immune intervention against tumors. Recent 
studies have demonstrated that two types of signals are needed 
to initiate a T cell response (2-6). Signal one is derived from 
the interaction of TCR with peptides presented by MHC 
class I and class II molecules, whereas signal two is derived 
from the costimulatory pathway. Failure to deliver either of 
these two signals may allow tumors to evade the immune 
system. Several tumors have been reported to evade immune 
surveillance by downregulation of MHC molecules, or other 
molecules critical for antigen presentation (7-9). For this cat- 
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egory  of tumors,  reintroduction of MHC  molecules or 
cytokines which upregulate the expression of MHC mole- 
cules, induces antitumor immune responses and rejection of 
the tumor (7-9). 
A  significant  proportion of tumors, however,  express a 
normal level of MHC antigen and present antigen normally. 
Over 15 yr ago, Talmage et al. first reported that a tumor 
cell line failed to induce an allogeneic T cell response despite 
its apparently normal expression  of MHC molecules (10). 
This original observation illustrated the concept that expres- 
sion of antigen alone is not suf~cient to activate T cells. This 
category of tumors, much like many nonhemapoietic cells, 
lacks costimulatory activity.  It is therefore of great interest 
to test if it is possible to augment tumor immunogenicity 
by enhancing their costimulatory activity. 
Recent studies have demonstrated that the B7 molecule 
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CD28 which has been demonstrated to transduce signals im- 
portant for T cell clonal expansion (11-15). In addition, fibro- 
blasts  transfected with B7/BB1 induce donal expansion of 
T cells (12, 16, 17). Antibodies or chimeric molecules that 
bind B7/BB1 block T cell donal expansion induced by anti- 
CD3, allogeneic MHC, and peptide/self-MHC (16-20).  Fur- 
thermore, the Fab fragment of anti-CD28 antibody 9.3 in- 
duces hyporesponsiveness  in alloreactive T cells (21), while 
intact anti-CD28 mAb rescues donal anergy induced by fixed 
APCs pulsed with specific peptides (15). Taken together, these 
results demonstrate that B7/BB1 fulfills the function origi- 
nally assigned to costimulators. It is thus feasible to enhance 
antitumor immune responses by introducing the B7/BB1 mol- 
ecule into the tumor cells. 
Recently, three laboratories reported that transfection of 
B7/BB1 molecule can successfully induce rejection ofa MHC 
class II-positive melanoma (22, 23) and a sarcoma transfected 
with MHC dass II (24). In those studies, B7/BB1 was shown 
to function at the induction phase of T cell response. In this 
report, we investigated the effect of B7/BB1 on the induc- 
tion, recruitment, and effector function of CD8 T  cells by 
introducing B7/BB1 into a MHC class II-negative plasmacy- 
toma, J558. Our results demonstrate that costimulatory  mol- 
ecules are required for ef[icient induction, recruitment, and 
effector function of antitumor CD8 T  cell responses. 
Materials and Methods 
Cell Lines and Experimental Animals.  Plasmacytoma  J558, thy- 
moma EL4 cells, and a macrophage cell line P388D1 (American 
Type Culture Collection, gockvilh, MD) were cultured in RPMI 
medium containing 5% FCS and 100/zg/ml penicillin and strep- 
tomycin. BALB/cByJ  and CBA/CaJ mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME). Male mice  between 6 and 
12 wk old were used in this study. 
Antibodies.  Anti-B7  mAbs 1D5, 3A12, and 7A5 were produced 
in  this laboratory and have been described fully (25); 16.10A1 
(26) was kindly provided by Dr. Hans Reiser (Dana-Farber Cancer 
Institute, Boston, MA). Other antibodies used were: Anti-PC.1 
(4G6, a kind gift from Dr. Dumont, Merck, Sharp & Dohme Re- 
search Laboratories, Rahway, NJ, reference 27); anti-lymphocyte 
function-associated  antigen 1 (LFA-1)  1 (M1/17, reference 28); anti- 
MHC class I (K44, reference 29); anti-MHC class II I-A  d (MDK6, 
reference 30); anti-VB antibodies V~/2 (B20.6, provided  by Dr. Kap- 
pler and Dr. Marrack, National Jewish Center for Immunology 
and Respiratory Diseases, Denver, CO), 3 (KJ-25, reference 31), 
6 (PK4-7, reference 32), 7 (TR310, reference 33), 8 (F23.1, refer- 
ence 34), 11 (PR3-15, references 35, 36), 14 (14-2, reference 37); 
anti-CD4 (GK1.5, reference 38); anti-CD8 (53.6.7, reference 39; 
and 2.43, reference 40). 
Plasraid Construction and Transfection ofJ558 Cells and EL4 Cells. 
PSRce vector containing resistance gene for neomycin (G418) was 
kindly provided by Dr. Norvak of Yale University (New Haven, 
CT). The murine BT/BB1 gene in pLN vector was provided by 
Dr. Linsley (Bristol-Myers  Squibb Pharmaceutical Research Insti- 
1 Abbreviations used in this paper'. MFC, mean  fluorescence  channel;  LFA-1, 
lymphocyte function-associated antigen 1;  TIL, tumor-infiltrating 
lymphocytes. 
tute, Seattle, WA). pLN-B7/BB1 was linearized with XbaI and 
inserted into pSRot at the XbaI site, resulting in a pSRo~-B7/BB1 
construct.  5  x  106 J558 cells were transfected with 50/~g of 
pSRot-B7/BB1 or pSRot plasmids by electroporation. The trans- 
fected cells were selected at 48 h after electroporation with RPMI- 
FCS medium containing G418 (0.6 mg/ml; Sigma Chemical Co., 
St. Louis, MO). The surviving colonies were stained with anti-B7 
antibodies and positive clones amplified. 
Tumorigenicity Assay.  Given  numbers of  J558-B7 or J558-Neo 
cells were suspended  in 100 #1 of PBS and injected subcutaneously 
in the inguina. The tumor incidence  was observed every  other day. 
Tumors >3 mm in diameter were scored as positive tumors. 
Cross-protection Experiment.  Two different protocols were used 
to analyze the cross-protection between J558-B7 and J558-Neo. 
First, in coinjection experiments, 5  x  10  ~ J558-Neo cells were 
mixed with either 5  x  10  +  or 10  x  10  ~  J558-B7 cells and injected 
subcutaneously into syngeneic BALB/cByJ  mice; the tumor inci- 
dence of the coinjected  mice was compared  with mice injected  with 
either  J558-Neo orJ558-B7 alone. 15 mice  were used for each  group. 
Second, in challenge experiments, BALB/c  mice were injected sub- 
cutaneously with either PBS, 5  x  106 J558-B7 cells, or 5  x  10  + 
J558-Neo in the left inguen. I wk later, all mice were challenged 
with 5  x  106 J558-Neo tumor cells subcutaneously in the right 
inguen. These distinct sites allow identification of the origin of 
the tumor. The tumor incidence was calculated from each group 
of 10 mice. 
Analysis  of Tumor-infiltrating Lxrapkocytes  by Flow  Cytometry. 
J558-B7 and J558-Neo tumors were excised from mice that were 
inoculated subcutaneously  with J558-B7 or J558-Neo tumor cells, 
respectively. Single cell suspensions were prepared by grinding 
tumors with frosted glass slides. Viable cells were isolated by cen- 
trifugation through a bed of  Ficoll-Hypaque  solution. These viable 
cells were analyzed by single or two-color flow cytometry. 
Single color assay,  pSR~-neo or pSRc~-BT/BBl-transfected  J558 
cells were incubated with either rat or hamster mAbs at 4~  for 
30 rain. Unbound mAbs were washed away by three consecutive 
washes with cold PBS containing 1% newborn bovine serum and 
0.1% sodium azide. The bound mAbs were detected with either 
FITC-labeled mouse anti-rat IgG (.Accurate Chemical & Science 
Corp., Westbury, NY) or FITC-labeled goat anti-hamster  IgG 
(Caltag Laboratories, S. San Francisco, CA). The fluorescence  was 
analyzed using FACSean  |  (Becton Dickinson & Co., Mountain 
View, CA). 
Two-color flow cytometry. The percentage of CD4 and CD8 
T cells was determined using a mixture of FITC-labeled  anti-CD4 
mAb and phycoerythrin-labeled  anti-CD8 mAb (PharMingen, San 
Diego, CA). The data shown are the percentage of  certain popula- 
tions of T cells among total lymphocytes  gated on the basis of for- 
ward scatter and side scatter. To analyze the V~ usage of the CD8 
T cells from tumor or from spleen, we used phycoerythrin-hbeled 
anti-CD8 mAb to label CD8 T cells. The cells stained  with anti-VB 
mAbs and second-step reagents were washed three times and were 
incubated with normal rat Ig (1 mg/ml; Chemicon International 
Inc., Temecula, CA) for 30 min to block the unsaturated binding 
sites of goat anti-hamster Ig or mouse anti-rat Ig. Phycoerythrin- 
labeled anti-CD8 mAb was added at 1:100 dilution, incubated for 
30 rain, and washed three times. The data shown are the percen- 
tages of CD8 T cells that bound specific  anti-V~ antibodies, with 
that of the nonspecific  binding in the absence of anti-VB antibodies 
subtracted. All samples were fixed with 1% paraformaldehyde  be- 
fore analysis by FACS  | 
Cytotoxic T Cell Assay.  The cytotoxicity of T cells was deter- 
mined in a 6-h SlCr release assay (39). Two populations of CD8 
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BALB/cByJ  spleens  by two rounds of treatment with complement 
and a cocktail of antibodies, including anti-B220 mAb KA3-3A1/ 
6.1, anti-CD4 mAb 2B6.2D8, anti-Mac-1 mAb M1/70.15.11.SH, 
and anti-HSA mAb Jlld. The CD8 T cell preparation contained 
>80% CD8 T cells and no detectable CD4 T cells, or B cells. The 
second group of effector cells were isolated from tumors. Briefly, 
a  single cell suspension prepared from J558-B7 tumors  (2  x 
107/ml) was incubated with 1:200 dilution of the anti-PC.1 ascites 
for 45 min. Unbound mAb was washed away and the antibody- 
coated cells  were incubated with goat anti-rat IgG (10/*g/ml) plus 
1:6 dilution of low-tox rabbit complement (Accurate Chemical & 
Science Corp.) for 45 min. P388D1, J558-Neo, and several inde- 
pendent lines of B7/BB1 transfected  J558 cells were labeled with 
51Cr and used as target cells. The released SlCr was determined 
using a 1205/3-plate counter (Pharmacia LKB, Piscataway, NJ). 
Briefly, 50/*1 of each supernatant was mixed with 250/*1 scintilla- 
tion fluid in a 96-well T-tray (Cat. No. 1205-451; Pharmacia LKB) 
and sealed  by T-tray tape sealer (Cat. No. 1205-452; Pharmacia  LKB). 
This method is generally ~10-fold more sensitive than the con- 
ventional gamma-counter. The percentage of specific release was 
calculated as described (41). 
In  Vivo Depletion of T  Cells.  Mice were injected with 300 
/,g/mouse of either normal rat Ig, anti-CD4 mAb GK1.5, or anti- 
CD8 mAb 2.43 at 48 h before, 48 h after, and 6 d after tumor 
inoculation. The efficiency  of  depletion was analyzed  by flow cyto- 
metric analysis of CD4 and CD8 T cells in the spleen. 
Results 
Transfection ofJ558  Cells  with B7/BB1.  J558 cells were 
transfected with either pSKcz-B7/BB1  or parental vector 
pSRc~. The cell surface expression of B7/BB1 in G418-resistant 
clones was determined by flow cytometry  using anti-B7 mAbs. 
Of 17 clones that expressed  B7/BB1, one clone, J558-B7, 
was characterized and the cell surface expression of a number 
of cell surface antigens was compared with J558 cells trans- 
fected with vector alone, J558-Neo, by flow cytometry. As 
shown in Fig. 1, J558-B7 expresses a significant amount of 
B7/BB1, whereas J558-Neo does not express any detectable 
amount of B7/BB1. J558-B7 and J558-Neo express identical 
levels of MHC class I. They both lack detectable MHC class 
II  and LFA-1.  Further experiments  showed that  CD45- 
tumor cells from freshly excised tumors fail to express MHC 
class II and all MHC class II + cells in the tumor are CD45 § 
inflammatory cells (data not shown). J558-B7 is also signifi- 
cantly more competent in stimulating allogeneic T  cell re- 
sponses than J558-Neo cells (data not shown). Thus, J558-B7 
expresses significant amounts of B7/BB1 and has costimula- 
tory activity for CD8 T  cells. 
B7-transfected J558  Cells Induce a CD8  T  Cell-dependent, 
CD4  T  Cell-independent  Tumor Rejection.  To test whether 
expression orB7 will reduce the tumorigenicity ofJ558 cells, 
we compared the tumor incidence in syngeneic mice that were 
injected with J558-B7  or J558-Neo.  As shown in Fig.  2, 
J558-B7  gives a significantly reduced tumor incidence and 
delayed tumor onset when injected into syngeneic BALB/c 
ByJ mice, as compared with J558-Neo. Mice injected with 
J558-Neo developed tumors between I and 2 wk; the tumor 
incidence correlated with the number of tumors cells injected. 
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Figure 1.  Analysis of cell surface phenotype of J558-B7 and J558-Neo 
by flow cytometry.  The tumor cells were incubated  with anti-B7  anti- 
MHC class I, class II, and LFA-1 mAbs. The binding of these mAbs was 
detected by FITC-labeled second-step reagents. 5,000 events were analyzed 
for each sample. 
In contrast, the tumor incidence in mice injected with J558- 
B7 showed a reciprocal relationship with the number of tumor 
cells injected. Mice that received  5  x  106 J558-B7  tumor 
cells had a significantly  lower tumor incidence than mice that 
received 1.25  x  106 J558-B7 tumor cells. 50% of mice that 
received  5  x  106 J558-B7  never  developed  tumors during 
the 8-too study. This reciprocal relationship is consistent with 
the notion that J558-B7 is a immunogen, and the reduced 
tumor incidence was due to antitumor immune responses. 
To test the role of CD4 and CD8 T cells in the rejection 
of  J558-B7 tumor, we injected anti-CD4 or anti-CD8 mAbs 
to eliminate CD4 and CD8 T  cells in vivo and compared 
the incidence in mice depleted of either CD4 or CD8 T cells. 
As shown in Fig. 3, injection of anti-CD8 mAb significantly 
increased the tumor incidence in mice that received J558-B7, 
whereas injection of anti-CD4 antibody failed to do so (Fig. 
3). This result indicates that tumor rejection depends on CD8 
but not CD4 T cells. This result also rules out the possibility 
that the reduced tumor incidence of J558-B7 is due to the 
intrinsic growth characteristic  of J558-B7. 
Expression of  B7/BB1 on Tumor Cells Induces Selective CD8 
T Cell Recruitment into the Tumors.  We have phenotyped the 
tumor-infiltrating lymphocytes (TIL) by flow cytometry. As 
shown in Fig. 4, the J558 cells and spleen cells can be differen- 
tiated by their forward scatter and side scatter.  This makes 
it possible  to  quantify the lymphocyte infiltration in  the 
tumors. As shown in Fig. 4 a, substantial numbers (35%) 
of viable cells recovered from J558-B7 tumors are lympho- 
cytes, whereas only about 7% of the viable cells recovered 
from J558-Neo tumors are lymphocytes. It is interesting to 
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note that CD8 T cells preferentially infiltrated the J558-B7 
tumors.  TIL  from  the  J558-B7--derived  tumor  have  a 
CD4/CD8 ratio of 0.35; spleen T cells in the same mice have 
a ratio of 3; the TIL from J558-Neo-derived tumor have a 
CD4/CD8  ratio dose to that of spleen cells (Fig.  4  b). 
Despite this sdective recruitment ofCD8 T cells, the CD8 
Table  1.  V~ Usage of CD8 T  Cells in Spleen of  J558-B7 
Tumor-bearing Mice and in the TIL 
V/~  TIL CD8  T  ceils  Spleen  CD8  T  ceils 
% 
2  2.3  6.7 
3  7.4  8.2 
6  12.2  10.0 
7  4.4  9.3 
8  45.5  37.8 
11  2.2  5.0 
14  1.9  6.0 
Total  75.9  80.0 
Spleen cells or tumor cell suspensions were dually stained with phyco- 
erythrin-labeled  anti-CD8 mAb and anti-VB mAbs detected by a FITC- 
labeled second-step reagent.  The data shown are percentages  of V~ + T 
cells among CD8 T  cells. 20,000  events were analyzed  per  sample. 
Figure  2.  Tumor  incidence  in 
syngencic BALB/cByJ  mice injected 
with 5  x  106 (a),  2.5  x  106 (b), 
or 1.25  x  106 (c) of J558-B7 (solid 
circles)  or J558-Neo (open c/rc/es). The 
tumor inddence was calcuhted from 
groups of four or five mice. Tumor 
cells were injected subcutaneously 
and tumors were scored by physical 
examination;  tumors that  were 3 
mm  or  above  in  diameter  were 
scored positive. All positive tumors 
scored at an early stage eventually 
grew into large visible tumors of 
>20 mm in diameter. 
T cells are polyclonal in terms of their V/3 usage (Table 1). 
The TIL are slightly enriched for V/38 + T cells and reduced 
for V~2,  11, and 14 positive T  cells. Nevertheless, most of 
the V~ tested are well represented among the TIL. 
Table  2.  Cross-protection  Between J558-Neo  and J558-B7 
Tumor  Inddence 
Primary  Secondary  Primary  Secondary 
Expt.  1:  Coinjection 
J558-Neo  -  14/15 
J558-B7  3/15 
J558-B7+J558-Neo  15/15 
Expt.  2:  Preimmunization 
J558-Neo  J558-B7  10/10  2/10 
J558-Neo  J558-Neo  10/10  9/10 
J558-B7  J558-Neo  2/10  8/10 
J558-Neo  -  10/10  - 
J558-B7  -  2/10  - 
For primary injection, 5  x  106 tumor cells were injected subcutaneously 
in the left inguen, and 8 d later, the second inoculation  of equal number 
of tumor cells were injected subcutaneously in the right inguen. The data 
shown in Expt.  1 are the tumor incidence on day 19 post injection.  In 
Expt. 2, the tumor incidence shown was scored at 19 d after secondary 
injection  and  27 d  after  primary injection. 
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Expression of B7/BB1 on the Tumor Cell Surface Is Required 
for Host Rejection of Tumors.  The J558-B7  cells do not in- 
duce protection against the challenge injection of  J558-Neo. 
As shown in Table 2, in coinjection experiments which have 
15 mice/group,  tumor incidence in the group that was in- 
jected with J558-Neo is comparable with the group that was 
coinjected with equal amount ofJ558-B7 andJ558-Neo. Simi- 
larly,  in  another  experiment,  mice  coinjected  with  107 
J558-B7  and 5  x  106 J558-Neo have a similar tumor inci- 
dence as the group  injected with 5  x  10  ~ J558-Neo cells 
(data not shown). To ascertain whether the tumor was de- 
rived from J558-Neo,  we injected mice first with J558-B7 
cells and subsequently with J558-Neo at a distant site. As 
shown in Table 2, preinjection of J558-B7 also failed to pro- 
tect against a subsequent injection  of J558-Neo.  Thus,  all 
three experiments fail to show any cross-protection of  J558- 
Neo by J558-B7. 
BT/BB1 Acts as an Accessory Molecule at the Effector Phase 
in CTL Response.  To understand the mechanism of this B7- 
dependent rejection, we isohted TIL by depleting tumor cells 
with complement  plus an mAb specific for PC.l, a plasma 
cell antigen which is expressed on J558 tumor cell surface. 
The freshly prepared TIL were tested for their cytotoxicity 
to the tumor cells. As shown in Fig.  5 a,  the TIL have a 
very potent cytotoxicity against J558-B7 ceils. However, the 
lysis of  J558-Neo cells is about 80-fold less ef~dent than J558- 
B7. In five independent experiments (data not shown), the 
Figure 3.  Requirement of CD8 but not CD4 T cells for tumor rejec- 
tion. BALB/cByJ  mice were injected  on day  -2, and day 2, and day 6 
with 300 #g/mouse of either normal rat Ig, anti-CD4 mAb GK1.5, or 
anti-CD8 mAb 2.43, intraperitoneally. On day 0, 5  x  106 J558-B7  cells 
were injected mbcutaneously.  Tumor inddences were calculated  from groups 
of 11 mice each. The efficacy  of the depletion  of T cell subsets was moni- 
tored by flow cytometry on day 21 when all groups of mice were sacrificed. 
A similar depletion of CD4 and CD8 T  subsets was achieved by their 
respective antibodies. 
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Figure 4.  Analysis  of inflammatory cells  by flow 
cytometry. (a) Quantitation of tumor-infiltrating 
lymphocytes in J558 tumors. Viable cells were iso- 
lated from tumors by grinding with frosted glass 
slides fo/lowed by centrifugation through Hcoll- 
Hypaque gradient.  The lymphocytes were gated 
on the basis of forward scatter and side scatter. The 
tumor derived from J558-Neo is composed of 7% 
infiltrating lymphocytes,  wher~s that derived from 
J558-B7 is composed of 35% infiltrating  lympho- 
cytes. The normal spleen cells and culuL,  ed J558-B7 
cells were used as controls￿9 (b) The CD4/CD8 T 
cell ratio in J558-B7  or J558-Neo derived tumors. 
Spleen  cells  or tumor cell suspensions were in- 
cubated with a mixture of phycoerythrin-labeled 
anti-CD8 and FITC-labeled anti-CD4 antibodies. 
The percentages of CD4 or CD8 T cells  were mea- 
sured by two-color flow cytometry. TIL were gated 
based on the side scatter and forward scatter. The 
data shown are means of CD4/CD8 ratios from 
four individual tumor-bearing mice in each group. 
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Figure 5.  The TIL preferentially lyse B7/BB1 transfected 
J558 cells. (a) Lysis of J558-B7 and J558-Neo  by the TIL. 
(b) CTL activity of normal CD8 T cells. TIL were isolated 
by depleting tumor cells with anti-PC.1 mAb followed by 
goat anti-rat IgG plus complement. Normal CD8 T cells  were 
isolated from BALB/c mouse spleens as described in Materials 
and Methods.  CTL activity was determined by a 6-h slCr 
release assay. 
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TIL lysed J558-B7 between 10- and 80-fold more efficiently 
than J558-Neo. This lysis requires prior priming of CD8 T 
cells because CD8 T cells isolated from syngeneic mice that 
did not receive a tumor injection have very low cytotoxicity 
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Figure 6.  Characterization of the cytotoxicity of TIL. (a) The cytotox- 
icity is mediated by CD8 T cells. The TIL were treated with either C' 
or C' plus anti-CD8 mAb and used as effector T cells. The number of 
effectors was calculated based on the number of TIL before depletion. (b) 
Blocking ofTIL cytotoxicity by anti-CD8 mAb 2.4,3, The maximal lysis 
(61%) was the specific lysis of J558-B7 at E/T  =  10, 
Figure 7.  B7/BB1 is not the target antigens recognized by the antitumor 
CTL. (a) Expression of B7/BB1 in J558-B7 (~p) and P388D1 (bottom). 
The tumor cells were stained with either second-step reagent alone (broken 
lines) or anti-B7 mAb 3A12 (solid lines), (b) Lysis of P388D1 and J558-B7 
by TIL isolated from J558-B7-derived tumors as determined in a 6-h SzCr 
release assay. 
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from B7/BB1, was not the target antigen recognized by the 
CTL. Another formal possibility is that a mutation in B7/BB1 
leads to generation of a mutant peptide that can be recog- 
nized by the CTL. Because the B7/BB1 eDNA we used for 
transfection has the correct sequence as determined  by DNA 
sequencing, the mutation(s) had to occur during the ampli- 
fication of the transfectants. To rule out this possibility, we 
tested five independent BT/BBl-transfectants  for their lysis 
by the CTL isolated from the TIL. All five transfectants are 
lysed "~10-fold more efficiently than J558-Neo (Table 3). As 
it is highly improbable to have the same mutation in all five 
independently derived transfectants, we are confident that the 
antigen recognized by the CTL is not derived from mutated 
B7. 
To directly demonstrate the role of B7/BB1  as an acces- 
sory molecule in the recognition ofJ558 by CTL, we tested 
whether the lysis of  J558-B7 is significantly  blocked by anti-B7 
mAb. As shown in Fig. 8, anti-B7 mAb 10.16A.1 inhibits 
CTL lysis of J558-B7 by >90%.  This result demonstrates 
that B7/BB1 can act as an accessory  molecule for CTL effector 
function. 
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Discussion 
A successful antitumor T cell response involves induction, 
recruitment, and effector function of T cells. Whereas the 
role of a major costimulatory molecule, B7/BB1, in induc- 
tion of T cell responses is well documented (11-21), the role 
of B7/BB1  in recruitment and effector function of T  cells 
is still not dear. Our studies reported here show that B7/BB1 
also plays an important role in the recruitment and effector 
function of antitumor T cells. 
E/T 
Figure 8.  Anti-B7/BB1  mAbs blocks CTL iysis of J558-B7. slCr- 
labeled  J558-B7 were incubated with TIL isolated from J558-B7-derived 
tumors in the presence or absence  of anti-B7 mAb 10.16A.1 (10 #g/ml) 
and the CTL lysis was determined in a 6-h assay. 
for  J558-B7 cells (Fig. 5 b). The cytotoxicity  measured is pre- 
dominantly mediated by CD8 T cells because treatment with 
anti-CD8 plus complement depletes most of the cytotoxicity 
(Fig. 6 a). In addition, the cytotoxidty  depends on CD8 mol- 
ecules expressed on the cell surface, because anti-CD8 mAb 
blocks the cytotoxicity in the absence of complement (Fig. 
6 b). Thus expression of B7/BB1 appears to be required for 
the effident recognition of the target by the antitumor CTL. 
B7/BB1 can either act as the antigen recognized by CTL 
or act as an accessory molecule at the effector phase of T cell 
recognition. Our results ruled out the possibility that B7 
donates peptides recognized by the CTL. As shown in Fig. 
7, P388D1, an H-2  a macrophage tumor line that expresses 
significant B7/BB1 on the cell surface cannot be lysed by the 
CTL, suggesting that B7/BB1 per se, or a peptide derived 
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Table 3.  Susceptibility of Five Independent B7/BBl-transfected 
J558 Cells to TIL Prepared  from J558-B7--derived Tumors 
Effector/target 
B7 expression 
J558  clones  (delta  MCF)  20  6.6  2.2  0.7  0.2  0.07 
B7/BBl-transfectants 
J558-B7  132  90.4  93.9  67.3  40.5  21.3  4.7 
laC5  113  72.6  87.9  62.9  36.9  18.9  7.2 
lcH1  75  70.2  83.0  49.5  25.9  12.7  4.4 
leD7  69  69.3  71.0  54.6  30.7  16.1  5.2 
lbH2  41  78.7  79.0  60.6  34.6  15.7  4.8 
Control 
J558-Neo  0  49.8  37.8  14.6  7.4  2.4  1.5 
Five independent B7/BBl-transfected  J558 clones and control J558-Neo 
were tested for their lysis by the TIL in a 6-h slCr release assay. The 
spontaneous  releases of the six clones  were all between 10.2 and 17.7%. 
The expression of B7 was analyzed  with an anti-B7 mAb 3A12, by flow 
cytometry. The data shown, the delta mean fluorescence  channel num- 
bers (MFC) was calculated  by subtracting MFC of the average of five 
negative clones from the MFC of the clones indicated. In agreement with two recent reports on B7/BBl-trans- 
fected melanoma (22, 23), B7/BBl-transfected plasmacytoma 
induces a potent tumor rejection response. This rejection is 
dependent on CD8 but not CD4 T cells. However, in con- 
trast to the two reports, we have been unable to demonstrate 
cross-protection between J558-B7  and J558-Neo,  either in 
coinjection experiments or in preimmunization experiments. 
This lack of cross-protection is consistent with the poor lysis 
of  J558-Neo by the CTL induced byJ558-B7. We have demon- 
strated that B7/BB1, either as an intact molecule or as a donor 
of peptides, was not recognized by the CTL as the antigen 
in two ways. First, P388D1,  a macrophage cell line (H-2  d) 
which expresses  MHC class I and class II plus significant 
amount of B7, was not lysed by the CTL. Second, the better 
recognition of J558-B7 was not due to mutant B7 peptides 
being recognized by CTL. As DNA sequencing revealed that 
the construct used for transfection has the wild-type B7 se- 
quence, the mutation in B7/BB1, if any, had to occur during 
and/or after transfection. Were it so, mutation would be ex- 
pected to be random and should occur at a very low frequency. 
We showed here that five independent B7/BB1 transfectants 
are lysed to a similar degree by the CTL, making it highly 
unlikely for a peptide derived from a B7-mutant to be the 
antigen. 
We have directly demonstrated that B7/BB1 acts as an ac- 
cessory molecule in the effector phase of the anti-tumor im- 
mune responses by showing that the lysis of  J558-B7 by the 
CTL can be blocked by the anti-B7 antibodies. Our finding 
that B7/BB1  is required at the effector phase of T  cell re- 
sponses  is in contrast to what has been reported by Chen 
et al. (22) and Harding and Allison (42) who showed that 
CTL induced by BT/BBl-transfected tumor lysed target cells 
with or without B7/BB1 equally well. This difference might 
be due to the amount and quality of adhesion molecules ex- 
pressed on tumor cells. The J558 tumor cells express unde- 
tectable levels of LFA-1 molecule. The B7/BB1 expressed in 
large quantity may enhance the interaction between T cells 
and target cells, much as adhesion molecules do. B7 binds 
CD28 with an affinity (2  x  10-7 M) comparable with that 
of LFA-1 intercellular adhesion molecule 1 (ICAM-1) inter- 
action. This interaction would be necessary for the interac- 
tion of T cells with J558 which express undetectable LFA-1. 
Consistent with the notion that B7/BB1 acts as an accessory 
molecule for CTL lysis in this model, we observed that in 
the tumors caused by J558-B7,  an overwhelming majority 
of the tumor cells have lost cell surface B7 expression during 
the course of tumor growth (data not shown). The loss of 
B7/BB1 allows these tumor cells to multiply even in the pres- 
ence of potent CTL activity. 
The mechanism by which of B7/BB1  functions at  the 
effector phase of T cell response has not been dearly defined. 
For anti-CD3 mAb redirected cytotoxicity, Lanier et al. have 
suggested that B7/CD28 interaction may provide a critical 
signal in inducing cytolytic activity of freshly isolated T cells 
(43,  44).  It is possible that B7/CD28 interaction may pro- 
vide a crucial signal to activate cytolytic activity of T cells, 
as well as enhancing T  cell/target cell adhesion. 
Quantitative analysis of TIL by flow cytometry revealed 
a role of B7/BB1 in the recruitment ofT cells in the tumors. 
Thus J558-B7-derived tumors have a significantly higher pro- 
portion of lymphocyte infiltrate than the J558-Neo tumors. 
More interestingly, CD8 T ceils are preferentially recruited 
into the tumor. The ratio of CD4/CD8  T  cells in spleen 
cells from both normal and tumor bearing mice is close to 
3:1; whereas the CD4/CD8 ratio in the tumor infiltrating 
lymphocytes in J558-B7-derived tumor is 0.35. In contrast, 
the infiltrate in J558-Neo-derived tumor consist of more CD4 
T  calls than CD8 T  cells.  The preferential recruitment of 
CD8 T calls into tumor sites resembles some earlier studies 
by Ceredig et al.  (45) and Liu et al.  (46) on inflammatory 
cells induced by viral infection of the central nervous system. 
This sdective recruitment ofCD8 T cells in this tumor model 
and in the virus-infected central nervous system is at least 
in part due to the lack of MHC class II expression. We have 
been unable to detect any MHC dass II in J558 cells main- 
tained in tissue culture or J558 cells freshly prepared from 
tumors. In the lymphocytic choriomeningitis virus-infected 
central nervous system, Allen et al.  showed that the T cell 
recruitment is restricted by MHC class I antigens (47). Thus 
lymphocyte infiltration into tissues seems to depend on both 
a costimulatory signal and a MHC antigen on the target tissue. 
One possible interpretation of this intriguing finding is that 
the tumor-infiltrating T  calls are derived from local clonal 
expansion of T ceils specific for tumor antigens, since donal 
expansion of T calls requires these two signals. This hypoth- 
esis would predict that all T cells in the tissues  are specific 
for the antigen presented.  This  appears  inconsistent with 
previous findings by Allen et al.  (47) who showed that in 
the inflammatory ceils isolated from the virus-infected cen- 
tral nervous system, only 1 of 100 of the T cells are specific 
for the viral antigen; most of the T  calls are bystanders. In 
addition, we show in this paper that all seven VB tested are 
well represented, which makes it very unlikely that T cells 
in the tumor are derived from clonal expansion of a few 
antigen-specific T ceils. We favor the hypothesis that the ini- 
tiation of the inflammation requires a specific T cell response. 
This response will lead to production of cytokine(s) that 
specifically attract T cells of the same subset. Recently, Tanaka 
et al. (48) reported that macrophage inflammatory factor (MIP- 
1B) selectively induces CD8 T cell chemotaxis and adhesion 
by binding to Pgp-1. 
Finally, it is worth mentioning that the TIL from theJ558- 
B7-derived tumors show a remarkable CTL activity in the 
absence of any in vitro stimulation. To our knowledge, such 
a "primary CTI2'  against  syngeneic tumors has not been 
reported before. This is certainly due to the enhanced im- 
munogenicity of tumor ceils by transfecting costimulatory 
molecule B7/BB1. Such potent in vivo anti-tumor CTL re- 
sponses would be very useful for the analysis of the specificity 
and regulation of anti-tumor CTL responses in vivo. 
Taken together, a successful anti-tumor T cell immune re- 
sponse involves at least three steps: recruitment of antigen- 
specific T cells into tumors; activation of T cells into effector 
T cells; and elimination of tumor cells by the effector T cells. 
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hance T cell responses at each of these three steps. It is worth 
noting that for tumors that lack molecules critical for the 
effector function of T ceils, a potent CTL response  against 
the tumor transfectant-expressing costimulatory molecule may 
not be sufficient to eliminate the parental tumor. 
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